CONMED Corporation Peer Comparison
Metric | Value | Ranking | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $1.9 Billion | 8/17 | STE $21.5B |
GMED $11.4B |
GKOS $7.9B |
ITGR $4.6B |
IRTC $3.5B |
LIVN $2.6B |
NUVA $2.1B |
CNMD $1.9B |
ATEC $1.5B |
HSKA $1.3B |
OFIX $690.1M |
SIBN $680.2M |
KIDS $603.2M |
SRDX $483.9M |
LUNG $276.8M |
ANIK $257.9M |
SGHT $129.9M |
Gross Margin | 57% | 12/17 | ATEC 100% |
SGHT 84% |
SIBN 79% |
GKOS 77% |
SRDX 75% |
LUNG 74% |
KIDS 73% |
NUVA 72% |
LIVN 71% |
IRTC 69% |
OFIX 69% |
CNMD 57% |
GMED 57% |
STE 44% |
HSKA 44% |
ITGR 16% |
ANIK 4% |
Profit Margin | 15% | 1/17 | CNMD 15% |
STE 11% |
LIVN 10% |
GMED 8% |
ITGR 5% |
NUVA 2% |
SRDX -12% |
OFIX -14% |
KIDS -15% |
HSKA -16% |
SIBN -16% |
GKOS -22% |
IRTC -31% |
SGHT -55% |
LUNG -69% |
ANIK -77% |
ATEC -83% |
EBITDA margin | 21% | 2/17 | LIVN 23% |
CNMD 21% |
NUVA 19% |
STE 17% |
GMED 8% |
ITGR 8% |
SRDX 0% |
OFIX -6% |
KIDS -10% |
HSKA -17% |
SIBN -19% |
GKOS -26% |
IRTC -34% |
SGHT -56% |
ANIK -66% |
LUNG -69% |
ATEC -184% |
Quarterly Revenue | $316.7 Million | 6/17 | STE $1.3B |
ITGR $746.3M |
GMED $625.7M |
LIVN $318.1M |
NUVA $317.8M |
CNMD $316.7M |
OFIX $196.6M |
IRTC $147.5M |
GKOS $96.7M |
HSKA $62.4M |
KIDS $54.6M |
ATEC $48.0M |
SIBN $40.3M |
ANIK $38.8M |
SRDX $29.9M |
LUNG $20.4M |
SGHT $20.2M |
Quarterly Earnings | $49.0 Million | 3/17 | STE $150.0M |
GMED $51.8M |
CNMD $49.0M |
ITGR $35.4M |
LIVN $33.0M |
NUVA $7.4M |
SRDX -$3.7M |
SIBN -$6.6M |
KIDS -$7.9M |
HSKA -$9.8M |
SGHT -$11.1M |
LUNG -$14.1M |
GKOS -$21.4M |
OFIX -$27.4M |
ANIK -$29.9M |
ATEC -$39.6M |
IRTC -$46.2M |
Quarterly Free Cash Flow | $47.8 Million | 4/17 | GMED $161.7M |
STE $148.8M |
ITGR $131.8M |
CNMD $47.8M |
LIVN $32.8M |
OFIX $32.1M |
IRTC $15.5M |
ANIK $3.8M |
SGHT $549,000 |
NUVA -$495,000 |
SIBN -$2.7M |
LUNG -$7.7M |
SRDX -$8.2M |
GKOS -$11.0M |
HSKA -$11.0M |
KIDS -$11.3M |
ATEC -$17.1M |
Trailing 4 Quarters Revenue | $1.3 Billion | 4/17 | STE $5.4B |
GMED $2.5B |
ITGR $2.0B |
CNMD $1.3B |
LIVN $1.2B |
NUVA $1.2B |
OFIX $784.2M |
IRTC $560.0M |
ATEC $470.0M |
GKOS $360.3M |
HSKA $254.9M |
KIDS $189.7M |
ANIK $164.2M |
SIBN $157.0M |
SRDX $125.4M |
SGHT $79.5M |
LUNG $60.0M |
Trailing 4 Quarters Earnings | $131.7 Million | 2/17 | STE $1.3B |
ITGR $746.3M |
GMED $625.7M |
LIVN $318.1M |
NUVA $317.8M |
CNMD $316.7M |
OFIX $196.6M |
IRTC $147.5M |
GKOS $96.7M |
HSKA $62.4M |
KIDS $54.6M |
ATEC $48.0M |
SIBN $40.3M |
ANIK $38.8M |
SRDX $29.9M |
LUNG $20.4M |
SGHT $20.2M |
Quarterly Earnings Growth | 209% | 4/17 | GMED 5094% |
NUVA 925% |
LIVN 550% |
CNMD 209% |
SIBN 34% |
GKOS 30% |
STE 30% |
ITGR 30% |
SGHT 15% |
ATEC 7% |
OFIX 5% |
LUNG 5% |
HSKA 2% |
IRTC -70% |
KIDS -72% |
ANIK -355% |
SRDX -365% |
Annual Earnings Growth | 131% | 2/17 | LIVN 737% |
CNMD 131% |
LUNG 32% |
OFIX 19% |
ITGR 15% |
SIBN 14% |
SGHT 12% |
ATEC 10% |
STE -11% |
GKOS -16% |
GMED -47% |
NUVA -50% |
HSKA -66% |
IRTC -82% |
KIDS -115% |
SRDX -175% |
ANIK -559% |
Quarterly Revenue Growth | 4% | 10/17 | GMED 63% |
KIDS 37% |
GKOS 24% |
SIBN 19% |
IRTC 18% |
LUNG 15% |
LIVN 11% |
OFIX 7% |
ITGR 6% |
CNMD 4% |
NUVA 2% |
SGHT 1% |
STE -1% |
SRDX -2% |
HSKA -4% |
ANIK -7% |
ATEC -59% |
Annual Revenue Growth | 2% | 12/17 | GMED 97% |
KIDS 20% |
SIBN 17% |
GKOS 13% |
IRTC 13% |
SRDX 10% |
LIVN 6% |
ITGR 6% |
OFIX 5% |
NUVA 4% |
STE 4% |
CNMD 2% |
ATEC 0% |
HSKA -5% |
ANIK -6% |
SGHT -12% |
LUNG -13% |
Cash On Hand | $38.5 Million | 13/17 | GMED $622.8M |
IRTC $519.5M |
LIVN $346.4M |
STE $172.2M |
HSKA $125.2M |
SGHT $118.6M |
GKOS $100.1M |
ATEC $81.0M |
NUVA $80.7M |
LUNG $63.3M |
ANIK $62.4M |
KIDS $51.0M |
CNMD $38.5M |
ITGR $35.6M |
SIBN $30.2M |
SRDX $30.1M |
OFIX $30.1M |
Short Term Debt | $717,000 | 14/17 | NUVA $360.8M |
STE $80.0M |
LIVN $22.0M |
IRTC $15.5M |
ITGR $13.9M |
GMED $11.0M |
ATEC $8.8M |
OFIX $7.0M |
HSKA $4.0M |
ANIK $2.3M |
SIBN $1.2M |
SRDX $1.0M |
LUNG $762,000 |
CNMD $717,000 |
KIDS $158,000 |
GKOS -$0 |
SGHT -$0 |
Long Term Debt | $940.1 Million | 3/17 | STE $2.3B |
ITGR $1.2B |
CNMD $940.1M |
IRTC $719.8M |
LIVN $604.3M |
ATEC $555.1M |
NUVA $545.4M |
GMED $523.5M |
GKOS $157.1M |
OFIX $130.2M |
HSKA $105.4M |
LUNG $55.0M |
SIBN $37.3M |
SGHT $34.2M |
SRDX $32.0M |
ANIK $25.2M |
KIDS $24.4M |
PE | 14.66 | 6/17 | GMED 125.00 |
LIVN 109.24 |
NUVA 73.28 |
STE 49.51 |
ITGR 40.57 |
CNMD 14.66 |
GKOS -1.00 |
IRTC -1.00 |
HSKA -1.00 |
SRDX -1.00 |
OFIX -1.00 |
KIDS -1.00 |
ANIK -1.00 |
ATEC -1.00 |
SIBN -1.00 |
LUNG -1.00 |
SGHT -1.00 |
PS | 1.50 | 16/17 | GKOS 21.98 |
IRTC 6.21 |
HSKA 5.14 |
GMED 4.62 |
LUNG 4.61 |
SIBN 4.33 |
STE 3.97 |
SRDX 3.86 |
ATEC 3.22 |
KIDS 3.18 |
ITGR 2.29 |
LIVN 2.08 |
NUVA 1.70 |
SGHT 1.63 |
ANIK 1.57 |
CNMD 1.50 |
OFIX 0.88 |
PB | 2.07 | 11/17 | IRTC 48.48 |
GKOS 11.85 |
SRDX 4.33 |
SIBN 4.12 |
STE 3.26 |
HSKA 3.14 |
LUNG 2.95 |
ITGR 2.84 |
GMED 2.81 |
NUVA 2.34 |
CNMD 2.07 |
LIVN 1.98 |
KIDS 1.63 |
ANIK 1.43 |
SGHT 1.37 |
OFIX 1.31 |
ATEC 0.00 |
PC | 50.19 | 4/17 | ITGR 129.50 |
STE 125.02 |
GKOS 79.09 |
CNMD 50.19 |
NUVA 25.83 |
OFIX 22.96 |
SIBN 22.51 |
ATEC 18.70 |
GMED 18.37 |
SRDX 16.05 |
KIDS 11.82 |
HSKA 10.46 |
LIVN 7.47 |
IRTC 6.70 |
LUNG 4.37 |
ANIK 4.14 |
SGHT 1.10 |
Liabilities to Equity | 1.48 | 2/17 | IRTC 11.68 |
CNMD 1.48 |
NUVA 1.34 |
ITGR 0.95 |
LIVN 0.93 |
LUNG 0.78 |
OFIX 0.65 |
STE 0.55 |
SGHT 0.51 |
SRDX 0.46 |
HSKA 0.42 |
GKOS 0.39 |
SIBN 0.38 |
KIDS 0.32 |
ANIK 0.29 |
GMED 0.25 |
ATEC 0.00 |
ROA | 0.06 | 1/17 | CNMD 6% | STE 4% | ITGR 4% | GMED 2% | LIVN 1% | NUVA 1% | HSKA -3% | KIDS -6% | SRDX -9% | OFIX -14% | GKOS -16% | SIBN -16% | IRTC -17% | ATEC -24% | LUNG -26% | SGHT -35% | ANIK -42% |
ROE | 0.14 | 2/17 | ATEC 13059% |
CNMD 14% |
STE 7% |
ITGR 7% |
NUVA 3% |
LIVN 2% |
GMED 2% |
HSKA -5% |
KIDS -8% |
SRDX -13% |
GKOS -22% |
OFIX -23% |
SIBN -23% |
LUNG -46% |
SGHT -53% |
ANIK -54% |
IRTC -210% |
Current Ratio | 1.67 | 15/17 | GMED 5.00 |
ANIK 4.49 |
KIDS 4.13 |
SIBN 3.66 |
GKOS 3.59 |
HSKA 3.39 |
SRDX 3.15 |
SGHT 2.95 |
STE 2.82 |
OFIX 2.54 |
LUNG 2.28 |
LIVN 2.08 |
ITGR 2.05 |
NUVA 1.75 |
CNMD 1.67 |
IRTC 1.09 |
ATEC 1.00 |
Quick Ratio | 0.03 | 16/17 | GMED 125.00 |
LIVN 109.24 |
NUVA 73.28 |
STE 49.51 |
ITGR 40.57 |
CNMD 14.66 |
GKOS -1.00 |
IRTC -1.00 |
HSKA -1.00 |
SRDX -1.00 |
OFIX -1.00 |
KIDS -1.00 |
ANIK -1.00 |
ATEC -1.00 |
SIBN -1.00 |
LUNG -1.00 |
SGHT -1.00 |
Long Term Debt to Equity | 1.01 | 2/17 | IRTC} 10.03 |
CNMD} 1.01 |
ITGR} 0.71 |
NUVA} 0.61 |
LUNG} 0.59 |
LIVN} 0.46 |
SGHT} 0.36 |
STE} 0.35 |
SRDX} 0.29 |
HSKA} 0.25 |
OFIX} 0.25 |
GKOS} 0.24 |
SIBN} 0.23 |
ANIK} 0.14 |
GMED} 0.13 |
KIDS} 0.07 |
ATEC} -407.54 |
Debt to Equity | 1.01 | 3/17 | IRTC 10.25 |
NUVA 1.02 |
CNMD 1.01 |
ITGR 0.72 |
LUNG 0.59 |
LIVN 0.48 |
STE 0.36 |
SGHT 0.36 |
SRDX 0.30 |
HSKA 0.26 |
OFIX 0.26 |
GKOS 0.24 |
SIBN 0.23 |
GMED 0.13 |
KIDS 0.07 |
ANIK 0.01 |
ATEC -413.99 |
Burn Rate | -3.43 | 14/17 | SGHT 9.54 |
HSKA 8.35 |
IRTC 6.59 |
SRDX 5.81 |
KIDS 5.71 |
LUNG 3.83 |
GKOS 3.62 |
SIBN 3.61 |
ITGR 2.48 |
ANIK 1.98 |
ATEC 1.26 |
OFIX 0.88 |
NUVA 0.77 |
CNMD -3.43 |
STE -4.48 |
GMED -22.13 |
LIVN -105.16 |
Cash to Cap | 0.02 | 14/17 | SGHT 0.91 |
ANIK 0.24 |
LUNG 0.23 |
IRTC 0.15 |
LIVN 0.13 |
HSKA 0.10 |
KIDS 0.08 |
SRDX 0.06 |
GMED 0.05 |
ATEC 0.05 |
NUVA 0.04 |
OFIX 0.04 |
SIBN 0.04 |
CNMD 0.02 |
GKOS 0.01 |
STE 0.01 |
ITGR 0.01 |
CCR | 0.98 | 8/17 | ITGR 3.72 |
GMED 3.12 |
SRDX 2.24 |
KIDS 1.43 |
HSKA 1.13 |
LIVN 1.00 |
STE 0.99 |
CNMD 0.98 |
LUNG 0.54 |
GKOS 0.52 |
ATEC 0.43 |
SIBN 0.42 |
SGHT -0.05 |
NUVA -0.07 |
ANIK -0.13 |
IRTC -0.34 |
OFIX -1.17 |
EV to EBITDA | 43.12 | 6/17 | SRDX} 23181.03 |
GMED} 236.00 |
STE} 108.00 |
ITGR} 98.99 |
NUVA} 47.54 |
CNMD} 43.12 |
LIVN} 39.04 |
SGHT} -4.05 |
ANIK} -7.74 |
LUNG} -19.06 |
ATEC} -22.58 |
OFIX} -64.42 |
IRTC} -73.46 |
SIBN} -90.21 |
KIDS} -103.62 |
HSKA} -124.13 |
GKOS} -323.48 |
EV to Revenue | 2.20 | 14/17 | GKOS 22.14 |
IRTC 6.60 |
HSKA 5.08 |
GMED 4.58 |
LUNG 4.49 |
SIBN 4.38 |
STE 4.37 |
ATEC 4.25 |
SRDX 3.88 |
KIDS 3.04 |
ITGR 2.86 |
NUVA 2.37 |
LIVN 2.31 |
CNMD 2.20 |
ANIK 1.21 |
OFIX 1.02 |
SGHT 0.57 |